Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 205, Issue 1, Pages 12-27Publisher
OXFORD UNIV PRESS
DOI: 10.1111/cei.13599
Keywords
endothelial cells; endothelial‐ to‐ mesenchymal transition; systemic sclerosis
Categories
Ask authors/readers for more resources
Systemic sclerosis is an autoimmune disease characterized by vascular alterations and multi-organ fibrosis. The process of endothelial-to-mesenchymal transition plays a crucial role in the development of progressive fibrosis in SSc, and understanding this mechanism is important for identifying therapeutic targets.
Systemic sclerosis (SSc) is an autoimmune disease characterized by significant vascular alterations and multi-organ fibrosis. Microvascular alterations are the first event of SSc and injured endothelial cells (ECs) may transdifferentiate towards myofibroblasts, the cells responsible for fibrosis and collagen deposition. This process is identified as endothelial-to-mesenchymal transition (EndMT), and understanding of its development is pivotal to identify early pathogenetic events and new therapeutic targets for SSc. In this review, we have highlighted the molecular mechanisms of EndMT and summarize the evidence of the role played by EndMT during the development of progressive fibrosis in SSc, also exploring the possible therapeutic role of its inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available